GeneDx Holdings Corp.

WGS

US81663L2007

Healthcare Facilities & Services

Real-time Estimate Cboe BZX Other stock markets 10:28:04 2024-05-16 am EDT			5-day change	1st Jan Change
22.79 ^USD	+7.70%		+8.91%	+704.73%

Apr. 30	Health Care Flat Amid Mixed Earnings -- Health Care Roundup	DJ
Apr. 30	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

James Coffin to Leave Sema4 Holdings Corp. as President, and Chief Operating Officer

January 31, 2022 at 04:20 pm EST

Sema4 Holdings Corp. announced that James Coffin, Ph.D., the President, and Chief Operating Officer, will leave the company for personal reasons, effective February 1, 2022.

Latest news about GeneDx Holdings Corp.

Health Care Flat Amid Mixed Earnings -- Health Care Roundup	Apr. 30	DJ
Sector Update: Health Care Stocks Mixed Late Afternoon	Apr. 30	MT
Top Midday Gainers	Apr. 30	MT
TD Cowen Adjusts GeneDx Holdings' Price Target to $24 From $14, Keeps Buy Rating	Apr. 30	MT
BTIG Adjusts GeneDx Holdings' Price Target to $19 From $15, Keeps Buy Rating	Apr. 30	MT
Transcript : GeneDx Holdings Corp., Q1 2024 Earnings Call, Apr 29, 2024	Apr. 29
GeneDx Holdings Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
GeneDx Holdings Corp. Updates Earnings Guidance for the Year 2024	Apr. 29	CI
Genedx Announces Partnership with Komodo Health to Expand Access to World?S Largest Rare Disease Dataset	Apr. 23	CI
Goldman Sachs Adjusts GeneDx Holdings Price Target to $11 From $6, Maintains Neutral Rating	Apr. 15	MT
Health Care Down on a Mixed Growth View -- Health Care Roundup	Feb. 21	DJ
Earnings Flash (WGS) GENEDX HOLDINGS Posts Q4 Revenue $57.4M	Feb. 20	MT
Transcript : GeneDx Holdings Corp., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
GeneDx Holdings Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2024	Feb. 20	CI
GeneDx Shares Gain After Preliminary Q4 Revenue Outlook	Jan. 08	MT
Genedx Holdings Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023	Jan. 08	CI
GeneDx Holdings Corp.(NasdaqGS:WGS) dropped from S&P Global BMI Index	Dec. 18	CI
Genedx Holdings Insider Bought Shares Worth $161,368, According to a Recent SEC Filing	Nov. 20	MT
Genedx Holdings Insider Sold Shares Worth $1,140,027, According to a Recent SEC Filing	Nov. 17	MT
Transcript : GeneDx Holdings Corp., Q3 2023 Earnings Call, Oct 30, 2023	23-10-30
Earnings Flash (WGS) GENEDX HOLDINGS Reports Q3 Revenue $53.3M, vs. Street Est of $52.4M	23-10-30	MT
GeneDx Holdings Corp. Updates Revenue Guidance for the Full Year 2023	23-10-30	CI
GeneDx Holdings Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Genedx Holdings Corp. Announces Executive Appointments	23-09-11	CI

GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.

Sector

Healthcare Facilities & Services

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for GeneDx Holdings Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.16 USD

Average target price

15.25 USD

Spread / Average Target

-27.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
GENEDX HOLDINGS CORP.	+704.73%	553M
SONIC HEALTHCARE LIMITED	-15.71%	8.57B
RADNET, INC.	+66.03%	4.3B
SYNLAB AG	-9.63%	2.47B
DR. LAL PATHLABS LIMITED	-2.16%	2.46B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-42.54%	2.31B
NEOGENOMICS, INC.	-7.23%	1.93B
FLEURY S.A.	-19.35%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-41.24%	1.2B
METROPOLIS HEALTHCARE LIMITED	+10.26%	1.14B

Medical & Diagnostic Laboratories

GeneDx Holdings Corp.

Equities

WGS

US81663L2007

Healthcare Facilities & Services

James Coffin to Leave Sema4 Holdings Corp. as President, and Chief Operating Officer

Latest news about GeneDx Holdings Corp.

Chart GeneDx Holdings Corp.

Company Profile

Income Statement Evolution

Ratings for GeneDx Holdings Corp.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories